# CVS HEALTH Corp: Form 10-Q for the period ended Sep 30, 2012

- Company: [CVS HEALTH Corp](/companies/cvs.md) (CIK 64803)
- Form: 10-Q
- Filed: 2012-11-06
- Accepted by EDGAR: Nov 6, 2012, 16:58 ET
- Period: 2012-09-30
- Accession: 0001104659-12-074770
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/64803/000110465912074770/a12-19979_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/64803/000110465912074770/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-07-01 to 2012-09-30 | $30.23bn | us-gaap:Revenues |
| Revenue | 9 months, 2012-01-01 to 2012-09-30 | $91.74bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2012-07-01 to 2012-09-30 | $24.58bn | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months, 2012-01-01 to 2012-09-30 | $75.53bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2012-07-01 to 2012-09-30 | $5.65bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2012-01-01 to 2012-09-30 | $16.21bn | us-gaap:GrossProfit |
| Operating income | 3 months, 2012-07-01 to 2012-09-30 | $1.81bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-01-01 to 2012-09-30 | $4.92bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-07-01 to 2012-09-30 | $135.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-01-01 to 2012-09-30 | $399.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-07-01 to 2012-09-30 | $669.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2012-01-01 to 2012-09-30 | $1.77bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-07-01 to 2012-09-30 | $1.01bn | us-gaap:ProfitLoss |
| Net income | 9 months, 2012-01-01 to 2012-09-30 | $2.75bn | us-gaap:ProfitLoss |
| Diluted EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.79 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2012-01-01 to 2012-09-30 | $2.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.80 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2012-01-01 to 2012-09-30 | $2.15 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-07-01 to 2012-09-30 | 1,274,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2012-01-01 to 2012-09-30 | 1,290,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2012-01-01 to 2012-09-30 | $4.94bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2012-01-01 to 2012-09-30 | $1.31bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2012-01-01 to 2012-09-30 | $627.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2012-01-01 to 2012-09-30 | $4.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-09-30 | $1.23bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-30 | $18.88bn | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-30 | $64.80bn | us-gaap:Assets |
| Current liabilities | at 2012-09-30 | $13.26bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2012-09-30 | $9.21bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2012-09-30 | $5.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | at 2012-09-30 | $825.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2012-09-30 | $36.92bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |

## Market risk

As filed, 572 characters.

As of September 30, 2012, the Company did not have any interest rate, foreign currency exchange rate or commodity derivative instruments in place and believes its exposure to interest rate risk (inherent in the Company’s debt portfolio), foreign currency exchange rate risk and commodity price risk is not material. The Company entered into an accelerated share repurchase agreement on September 19, 2012 which subjects it to some equity price risk. See discussion of the accelerated share repurchase agreement in Note 4 to the condensed consolidated financial statements.

## Controls and procedures

As filed, 4,785 characters.

**Evaluation of disclosure controls and procedures:** The Company’s Chief Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15 (f) and 15d-15(f)) as of September 30, 2012, have concluded that as of such date the Company’s disclosure controls and procedures were adequate and effective and designed to ensure that material information relating to the Company and its subsidiaries would be made known to such officers on a timely basis.

**Changes in internal control over financial reporting:** There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the three months ended September 30, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### Part II Item 1

### Legal Proceedings

Certain legal proceedings in which we are involved are discussed in Part I, Item 3 of our 2011Annual Report on Form 10-K. The following discussion is limited to certain recent developments concerning our legal proceedings and should be read in conjunction with those earlier reports.

1\. Caremark was named in a putative class action lawsuit filed in October 2003 in Alabama state court by John Lauriello, purportedly on behalf of participants in the 1999 settlement of various securities class action and derivative lawsuits against Caremark and others. Other defendants include insurance companies that provided coverage to Caremark with respect to the settled lawsuits. The Lauriello lawsuit seeks approximately $3.2 billion in compensatory damages plus other non-specified damages based on allegations that the amount of insurance coverage available for the settled lawsuits was misrepresented and suppressed. A similar lawsuit was filed in November 2003 by Frank McArthur, also in Alabama state court, naming as defendants, among other, Caremark and several insurance companies involved in the 1999 settlement. This lawsuit was stayed as a later-filed class action, but McArthur was subsequently allowed to intervene in the Lauriello action. Following the close of class discovery, the trail court entered an Order on August 15, 2012 that granted the plaintiffs’ motion to certify a class pursuant to Alabama Rule of Civil Procedures 23(b)(3) but denied their request that the class also be certified pursuant to Rule 23(b)(1). In addition, the August 15, 2012 Order appointed class representatives and class counsel. The defendants have filed a notice of appeal with the Alabama Supreme Court and the plaintiffs have filed a notice of cross-appeal. The proceedings in the trial court are stayed by statute pending a decision on the appeal and cross-appeal by the Alabama Supreme Court.

2\. In March 2009, the Company received a subpoena from the Office of Inspector General (“OIG”) within the U.S. Department of Health and Human Services requesting information concerning the Medicare Part D prescription drug plans of RxAmerica, the PBM subsidiary of Longs Drug Stores Corporation which was acquired by the Company in October 2008. In October, 2012, RxAmerica reached a settlement with the OIG to pay $5.25 million, plus costs and other fees, to resolve issues related to RxAmerica’s 2007 and 2008 submission of pricing data for use in estimating certain generic drug prices on the Centers for Medicare and Medicaid Services Plan Finder website tool.

### Part II Item 2

### Unregistered Sales of Equity Securities and Use of Proceeds

(c) Stock Repurchases

The following table presents the total number of shares purchased in the three months ended September 30, 2012, the average price paid per share and the approximate dollar value of shares that still could have been purchased at the end of the applicable fiscal period, pursuant to the 2011 and 2012 Repurchase Programs. See Note 4 to the condensed consolidated financial statements.

| Fiscal Period | Total Number of Shares Purchased | Average Price Paid per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs |
| --- | ---: | ---: | ---: | ---: |
| July 1, 2012 through July 31, 2012 | 1,222,600 | $ 44.98 | 1,222,600 | $ 945,303,162 |
| August 1, 2012 through August 31, 2012 | 8,905,940 | $ 45.01 | 8,905,940 | $ 544,471,510 |
| September 1, 2012 through September 30, 2012 | 20,012,315 | $ 47.09 | 20,012,315 | $ 4,998,170,756 |
| Totals | 30,140,855 |  | 30,140,855 |  |

35

### Part II Item 6

### Exhibits

Filed Nov 6, 2012.
Source: SEC EDGAR, the filing index for accession 0001104659-12-074770. Last ingested by Listed: Nov 6, 2026, 17:47 ET. No prices; not investment advice.
